CN117815146A - 一种仿生保湿抗菌修复组合物 - Google Patents
一种仿生保湿抗菌修复组合物 Download PDFInfo
- Publication number
- CN117815146A CN117815146A CN202410019999.8A CN202410019999A CN117815146A CN 117815146 A CN117815146 A CN 117815146A CN 202410019999 A CN202410019999 A CN 202410019999A CN 117815146 A CN117815146 A CN 117815146A
- Authority
- CN
- China
- Prior art keywords
- compound
- moisturizing
- test
- bionic
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 52
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 17
- -1 guanidine compound Chemical class 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000008439 repair process Effects 0.000 claims abstract description 14
- 239000008213 purified water Substances 0.000 claims abstract description 12
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims abstract description 9
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920002101 Chitin Polymers 0.000 claims abstract description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract description 8
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960003237 betaine Drugs 0.000 claims abstract description 8
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 claims abstract description 7
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 claims abstract description 7
- 229940064064 purslane extract Drugs 0.000 claims abstract description 6
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 4
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 claims description 4
- 229920002413 Polyhexanide Polymers 0.000 claims description 4
- 229960004670 didecyldimethylammonium chloride Drugs 0.000 claims description 4
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 claims description 3
- 229940093424 polyaminopropyl biguanide Drugs 0.000 claims description 3
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 claims description 2
- SCXCDVTWABNWLW-UHFFFAOYSA-M decyl-dimethyl-octylazanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCC SCXCDVTWABNWLW-UHFFFAOYSA-M 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- 230000003592 biomimetic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 241000894006 Bacteria Species 0.000 abstract description 19
- 230000002147 killing effect Effects 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 10
- 230000014759 maintenance of location Effects 0.000 abstract description 7
- 206010059866 Drug resistance Diseases 0.000 abstract description 5
- 125000002091 cationic group Chemical group 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 239000000419 plant extract Substances 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 88
- 238000004659 sterilization and disinfection Methods 0.000 description 49
- 230000001954 sterilising effect Effects 0.000 description 48
- 239000011550 stock solution Substances 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 20
- 230000003472 neutralizing effect Effects 0.000 description 20
- 238000001514 detection method Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 239000001963 growth medium Substances 0.000 description 17
- 238000006386 neutralization reaction Methods 0.000 description 17
- 239000000725 suspension Substances 0.000 description 16
- 239000008055 phosphate buffer solution Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 241000186427 Cutibacterium acnes Species 0.000 description 9
- 229940055019 propionibacterium acne Drugs 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000010998 test method Methods 0.000 description 8
- 241000222122 Candida albicans Species 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 229940095731 candida albicans Drugs 0.000 description 7
- 239000000645 desinfectant Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 229960005150 glycerol Drugs 0.000 description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 6
- 241000223229 Trichophyton rubrum Species 0.000 description 6
- 230000003385 bacteriostatic effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 231100000989 no adverse effect Toxicity 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 210000000245 forearm Anatomy 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 231100000460 acute oral toxicity Toxicity 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000001965 potato dextrose agar Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000006916 nutrient agar Substances 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 244000178870 Lavandula angustifolia Species 0.000 description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 239000003245 coal Substances 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000001102 lavandula vera Substances 0.000 description 2
- 235000018219 lavender Nutrition 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000036559 skin health Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000010677 tea tree oil Substances 0.000 description 2
- 229940111630 tea tree oil Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- SFAYBQDGCKZKMH-UHFFFAOYSA-N BNCC Chemical compound BNCC SFAYBQDGCKZKMH-UHFFFAOYSA-N 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001103617 Pseudomonas aeruginosa ATCC 15442 Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明涉及生物医药技术领域,公开了一种仿生保湿抗菌修复组合物及,包括以下重量百分比组份:水解壳多糖0.05‑5%、季铵盐类化合物0.1‑5%、胍类化合物0.1‑5%、醇类化合物0.1‑20%、吡咯烷酮羧酸钠0.1‑20%、马齿苋提取物0.1‑10%、EDTA二钠0.05‑5%、甜菜碱0.1‑10%和纯化水25‑99.35%。本发明中的化合物与天然动植物提取物协同作用制备得到的组合物,在增强了保湿性的同时,协同增加了阳离子特性,有效地增加了其单一的抗菌范围,加速了杀灭细菌的速度,达到抗耐药相加作用。
Description
技术领域
本发明属于生物医药技术领域,具体地说,涉及一种仿生保湿抗菌修复组合物。
背景技术
目前,人类健康会受到多种有害病菌的影响。病毒和细菌的侵染会导致多种疾病。人类皮肤是保护人类健康的第一道屏障,保持人类皮肤健康尤为重要。影响人类皮肤健康外在因素包括有害污染物、有害病菌、温湿度、光辐射等,其中有害病菌及干燥对皮肤的健康影响尤为严重。
现有皮肤护理产品包括杀灭皮肤有害病菌产品和保湿产品。
现有的杀灭皮肤有害病菌产品技术方案主要包括以下几种:
抗生素和抗真菌药物:这类产品含有特定的化学物质,如氯己定、酮康唑、咪康唑等;酒精基消毒液:含有高浓度酒精(通常为60%—90%)的产品;氧化剂类:如过氧化氢、过氧乙酸等;酚类消毒剂:如煤酚皂、邻苯二甲醛等;天然抗菌成分:如茶树油、芦荟、薰衣草精油等;银离子技术。
现有的保湿产品技术方案主要包括以下几种:
吸湿剂:如透明质酸、甘油、尿囊素等;封闭剂:如矿物油、石蜡、羊毛脂等;润肤剂:如硅油、蜂蜡等;天然油脂和植物提取物:如椰子油、橄榄油、芦荟、海藻精华等;生物活性成分:如肽、生长因子、抗氧化剂等。
Winter课题组在1962年提出“湿性愈合”的理论(Formation of the scab andthe rate of epithelialisation of superficial wounds in the skin of the youngdomestic pig.British Journal of Experimental Pathology.1962;43(4):531-538),Hinman和Maibach也论证了湿性环境相比干燥环境,可以显著提高伤口愈合的速度。从而奠定了采用新型敷料处理创面的理论基础。基于这一思想的各种新式敷料得到广泛的发展,如水状胶体敷料、水凝胶敷料等。其中水凝胶敷料可以保持伤口局部湿润,有助于血管的正常化;同时可以保护新生肉芽组织不受损伤;保护末梢神经,减少疼痛;可以促进生长因子释放,促进创面的愈合。因此得到各国的普遍重视。
现有的杀灭皮肤有害病菌产品技术的缺点:
1、抗生素和抗真菌药物:这类产品含有特定的化学物质,如氯己定、酮康唑、咪康唑等,能够针对性地杀灭细菌或真菌。缺点是可能引发过敏反应,长期使用可能导致耐药性发展,以及可能破坏皮肤正常微生物群落。
酒精基消毒液:含有高浓度酒精(通常为60%—90%)的产品可以迅速杀灭大部分细菌和某些病毒。缺点是可能会引起皮肤干燥、刺激和过敏,对某些病毒和孢子效果不佳,且易燃。
氧化剂类:如过氧化氢、过氧乙酸等,通过释放活性氧来杀灭微生物。缺点是对某些微生物的杀灭效果有限,可能会对皮肤和眼睛产生刺激,且稳定性较差。
酚类消毒剂:如煤酚皂、邻苯二甲醛等,具有广谱杀菌作用。缺点是对皮肤和黏膜有刺激性,且对某些病毒和孢子效果不佳。
天然抗菌成分:如茶树油、芦荟、薰衣草精油等,具有一定的抗菌效果。缺点是效力可能较弱,且不同来源和品质的天然成分效果可能差异较大。
银离子技术:利用银离子的抗菌特性,通过抑制微生物生长或破坏其细胞结构来达到杀菌效果。缺点是成本较高,且过度使用可能造成环境中的银离子积累。
现有的保湿产品技术方案的缺点:
吸湿剂:如透明质酸、甘油、尿囊素等,能够吸引并保持皮肤表面和深层的水分。缺点是容易在保湿的同时滋生有害细菌。
封闭剂:如矿物油、石蜡、羊毛脂等,能够在皮肤表面形成保护层,减少水分蒸发。缺点是可能感觉油腻,不适合油性或易长痘的皮肤。
润肤剂:如硅油、蜂蜡等,能在皮肤表面形成防水屏障,防止水分流失。缺点是可能会堵塞毛孔,不适合敏感或痤疮肌肤。
天然油脂和植物提取物:如椰子油、橄榄油、芦荟、海藻精华等,提供保湿和营养成分。缺点是不同来源和品质的天然成分效果可能差异较大,且保湿的同时滋生有害细菌。
生物活性成分:如肽、生长因子、抗氧化剂等,旨在改善皮肤结构和功能,增强保湿效果。缺点是成本较高,且效果可能因个体差异而异。
以上技术无法兼顾皮肤保湿的同时持久广谱抗菌。
1、现有的杀灭皮肤有害病菌产品包括外用消毒剂和抗生素,上述大部分产品主要采用化学成分组成或制备得到,杀菌效果不佳或防治范围不大,长期使用容易导致病菌出现耐药性,且功效单一,易引起皮肤干燥。
2、现有的保湿类化妆品,虽然有一定的保湿效果,但抗菌性较差,使用后皮肤潮湿易滋生有害病菌。
3、通过上述分析,现有技术无法兼顾皮肤保湿的同时持久广谱抗菌。
为解决现有技术效果单一,无法满足皮肤兼顾保湿的同时持久广谱抗菌的问题。本发明创造的目的是提供一种兼顾皮肤保湿、广谱抗菌的组合物及其制备方法。
发明内容
为解决现有技术效果单一,无法满足皮肤兼顾保湿的同时持久广谱抗菌的问题,本发明采用技术方案的基本构思是:
一种仿生保湿抗菌修复组合物,包括以下重量百分比组份:水解壳多糖0.05-5%、季铵盐类化合物0.1-5%、胍类化合物0.1-5%、醇类化合物0.1-20%、吡咯烷酮羧酸钠0.1-20%、马齿苋提取物0.1-10%、EDTA二钠0.05-5%、甜菜碱0.1-10%和纯化水25-99.35%。
作为本发明的一种优选实施方式,所述的季铵盐类化合物为O-3,4-亚甲二氧基乙酸酯-N-三甲基壳聚糖季铵盐、双癸基二甲基氯化铵、辛基癸基二甲基氯化铵、十二烷基二甲基苄基氯化铵中一种或多种的混合物。
作为本发明的一种优选实施方式,所述的胍类化合物为聚六亚甲基双胍、聚氨丙基双胍、聚六亚甲基胍中一种或多种的混合物。
作为本发明的一种优选实施方式,所述的醇类化合物为乙醇、甘油、丙二醇、丁二醇、1,2-己二醇、苯氧乙醇、山梨醇中一种或多种的混合物。
6、本发明还公开一种仿生保湿抗菌修复组合物的制备方法,应用于权利要求1-4任意一项所述的一种仿生保湿抗菌修复组合物,其特征在于,包括一下制备步骤:
将水解壳多糖、季铵盐类化合物、胍类化合物、醇类化合物、吡咯烷酮羧酸钠、马齿苋提取物、EDTA二钠、甜菜碱依次加入纯化水中溶解均匀,得到仿生保湿抗菌修复组合物。
本发明中的仿生保湿抗菌修复组合物其广谱抗菌、保湿性是通过以下理论实现的:
水解壳多糖,广泛存在于甲壳类动物的外壳,也存在于一些绿藻中,属多糖类,呈阳离子性质,有极好的保湿效果。
季铵盐类化合物是阳离子表面活性剂,抑菌范围广,能有效地抑制革兰氏阳性菌、革兰氏阴性菌、酵母菌和真菌。其杀菌机理是:具有杀菌性能的阳离子基团强有力地吸附于细菌的表面,改变细菌细胞壁的通透性,使菌体内的酶、辅酶和代谢中间产物溢出,致使微生物停止呼吸功能而致死,从而达到杀灭病菌作用。
胍类化合物近年来应用越来越多,已被广泛应用于医药消毒、食品和其他日常生活用品的消毒。胍类消毒剂具有抗菌谱广,无色、无嗅、对皮肤无刺激性、无毒性、无腐蚀性的特点,被公认为21世纪最安全、无毒、高效的广谱抗菌剂。
吡咯烷酮羧酸钠是皮肤中天然存在的物质,是氨基酸衍生物,具有较强的吸湿性,可以从空气中吸收水分补充停留在皮肤中的保湿剂,达到长效保湿的目的。
甜菜碱是一种碱性物质,是易吸潮的鳞状或棱状结晶,具有强烈的吸湿性能,可以从空气中吸收水分补充停留在皮肤中的保湿剂,达到长效保湿的目的。
上述化合物与天然动植物提取物协同作用制备得到的组合物,在增强了保湿性的同时,协同增加了阳离子特性,有效地增加了其单一的抗菌范围,加速了杀灭细菌的速度,达到抗耐药相加作用。
本发明与现有技术相比具有以下有益效果:
本发明中的化合物与天然动植物提取物协同作用制备得到的组合物,在增强了保湿性的同时,协同增加了阳离子特性,有效地增加了其单一的抗菌范围,加速了杀灭细菌的速度,达到抗耐药相加作用。
附图说明
在附图中:
图1为本发明实验例对比结果柱状图。
具体实施方式
以下通过具体实施例来对本发明作进一步的说明,但这些实施例只是为了说明,不是对本发明的限制。
实施例1:仿生保湿抗菌修复组合物:
仿生保湿抗菌修复组合物,其特征在于由如下重量百分比的组分制成:水解壳多糖0.2%、双癸基二甲基氯化铵0.3%、聚氨丙基双胍0.1%、甘油3%、吡咯烷酮羧酸钠2%、马齿苋提取物2%、甜菜碱2%、EDTA二钠0.1%、余量为纯化水。
将水解壳多糖、双癸基二甲基氯化铵、聚氨丙基双胍、甘油、吡咯烷酮羧酸钠、马齿苋提取物、EDTA二钠、甜菜碱依次加入纯化水中溶解均匀,制得仿生保湿抗菌修复组合物溶液。
对比例1一种对比物(Ⅰ)
一种对比物(Ⅰ),其特征在于由如下重量百分比的组分制成:纯化水100%。
制备方法:蒸馏法制备所得。
对比例2一种对比物(Ⅱ)
一种对比物(Ⅱ)其特征在于由如下重量百分比的组分制成:甘油5%、纯化水95%。
制备方法:将甘油加入纯化水溶解均匀,即可。
对比例3一种对比物(Ⅲ)
一种对比物(Ⅲ)其特征在于由如下重量百分比的组分制成:透明质酸0.5%、纯化水99.5%。
制备方法:将透明质酸加入纯化水溶解均匀,即可。
试验例1保湿效果评价
评价方法:
依据中科检测技术服务(广州)股份有限公司CASTS/CEEC-TW-003-01《化妆品体外保湿功效测试方案-保湿率的测定(重量法)》(实验室方法)选用实施例1、对比例1-3制备的样品,测定样品的保湿效。
测试方法:
于干燥器的底层注入饱和硫酸铵溶液,达到恒湿状态。
每个样品在每个时间点平行三次实验。取规格为5cmx5cm的玻璃板,并贴上3M胶带。用多孔隔板将饱和硫酸铵隔开,将贴了胶带的玻璃板放平板上并盖好干燥器的盖子,静置20min后,称量此时玻璃板(含3M胶带)的重量m,精确至0.000lg。
将样品均匀涂抹在玻璃板上的3M胶带上,样品用量为(2.0±0.1)mg/cm2,立即称重为m0,精确至0.0001g。称量后立即放入恒湿干燥器上层静置。
静置1h、2h、4h、8h、24h、48h后,每个时间点各称量一次玻璃板(含3M胶带和样品)的重量mt,精确至0.0001g。
计算各个时间点样品的保湿率。
测试结果:
各时间点不同样品的平均保湿率,(见表1所示)(图1)
表1
结果表明,在各个时间点下各试验样品的保湿率顺序为:实施例1>对比例2>对比例3>对比例1,实施例1的保湿效果最好,有较好的保湿作用。
试验例2痤疮丙酸杆菌杀菌性能检测
试验菌种为痤疮丙酸杆菌ATCC11827菌种代数为第5代,中和剂为3.9%D/E中和肉汤,稀释液为0.03mol/L磷酸盐缓冲液(PBS),培养基为痤疮丙酸杆菌琼脂培养基。
检测方法:
依据中华人民共和国卫生行业标准WS/T 650-2019《抗菌和抑菌效果评价方法》5.2.1悬液定量杀菌试验。
杀菌试验:按照悬液定量杀菌试验方法,实施例1原液,作用时间2.5min、
5.0min、7.5min,试验重复3次。试验温度20℃±1℃。
检测结果:
痤疮丙酸杆菌的杀菌效果
经3次重复试验证明,在试验温度20℃±1℃的条件下,实施例1原液,作用2.5min,对痤疮丙酸杆菌的平均杀菌率为>99.9%。(见表2所示))。
表2表2实例1杀菌试验结果
注:阴性对照无菌生长
结果表明,经3次重复试验,实施例1原液,以3.9%D/E中和肉汤为中和剂,可有效中和残留实施例1对痤疮丙酸杆菌的作用,且中和剂及其中和产物对痤疮丙酸杆菌及培养基无不良影响。3次重复试验证明,实施例1原液,作用5.0
min,对痤疮丙酸杆菌的平均杀菌率为>99%,具有较强抗菌作用。
试验例3红色毛癣菌杀菌性能检测
试验菌种为红色毛癣菌(BNCC 340195)第3、4代,中和剂为D/E中和肉汤,稀释液为0.03mol/L磷酸盐缓冲液(PBS),培养基为马铃薯葡萄糖琼脂培养基
(PDA)。
检测方法:
依据中华人民共和国卫生行业标准WS/T 650-2019《抗菌和抑菌效果评价方法》第5.2.1.5项。
杀菌试验:按照悬液定量杀菌试验方法,实施例1原液,作用时间2.5min、5.0min、7.5min,试验重复3次。环境温度:22.5℃~23.2℃;相对湿度:47%。
检测结果:
红色毛癣菌杀菌试验
经3次重复试验证明,在试验温度20℃±1℃的条件下,实施例1原液,作用5.0min,对红色毛癣菌杀菌的平均杀菌率为>99.89%(见表3所示)
表3表3实施例1杀菌试验结果
注:阴性对照无菌生长
结果表明,经3次重复试验,实施例1原液,以D/E中和肉汤为中和剂,可有效中和残留实施例1对红色毛癣菌的作用,且中和剂及其中和产物对红色毛癣菌及培养基无不良影响。3次重复试验证明,实施例1原液,作用5.0min,对痤疮丙酸杆菌的平均杀菌率为>99%,具有较强抗菌作用。
试验例4大肠杆菌杀菌性能检测
试验菌种为大肠杆菌8099以上菌种代数为第5代,中和剂为3.9%D/E中和肉汤,稀释液为0.03mol/L磷酸盐缓冲液(PBS),培养基为营养琼脂培养基。
检测方法:
依据中华人民共和国卫生行业标准WS/T 650-2019《抗菌和抑菌效果评价方法》5.2.1悬液定量杀菌试验。
杀菌试验:按照悬液定量杀菌试验方法,实施例1原液,作用时间1min、2min、3min,试验重复3次。试验温度20℃±1℃。
检测结果:
大肠杆菌杀菌试验
经3次重复试验证明,在试验温度20℃±1℃的条件下,实施例1原液,作用1min,对大肠杆菌杀菌的平均杀菌率为>99.9%(见表4所示)
表4表4实施例1杀菌试验结果
注:阴性对照无菌生长
结果表明,经3次重复试验,实施例1原液,以3.9%D/E中和肉汤为中和剂,可有效中和残留实施例1对大肠杆菌的作用,且中和剂及其中和产物对大肠杆菌及培养基无不良影响。3次重复试验证明,实施例1原液,作用2min,对大肠杆菌的平均杀菌率为>99%,具有较强抗菌作用。
试验例5金黄色葡萄球菌杀菌性能检测
试验菌种为金黄色葡萄球菌ATCC6538以上菌种代数为第5代,中和剂为3.9%D/E中和肉汤,稀释液为0.03mol/L磷酸盐缓冲液(PBS),培养基为马铃薯葡萄糖琼脂培养基(PDA)。
检测方法:
依据中华人民共和国卫生行业标准WS/T 650-2019《抗菌和抑菌效果评价方法》5.2.1悬液定量杀菌试验。
杀菌试验:按照悬液定量杀菌试验方法,实施例1原液,作用时间1min、2min、3min,试验重复3次。试验温度20℃±1℃。
检测结果:
金黄色葡萄球菌杀菌试验
经3次重复试验证明,在试验温度20℃±1℃的条件下,实施例1原液,作用1min,对金黄色葡萄球菌的平均杀菌率为>99.9%(见表5所示)
表5表5实施例1杀菌试验结果
注:阴性对照无菌生长
结果表明,经3次重复试验,实施例1原液,以3.9%D/E中和肉汤为中和剂,可有效中和残留实施例1对金黄色葡萄球菌的作用,且中和剂及其中和产物对金黄色葡萄球菌及培养基无不良影响。3次重复试验证明,实施例1原液,作用2min,对金黄色葡萄球菌的平均杀菌率为>99%,具有较强抗菌作用。
试验例6铜绿假单胞菌杀菌性能检测
试验菌种为铜绿假单胞菌ATCC15442以上菌种代数为第5代,中和剂为3.9%D/E中和肉汤,稀释液为0.03mol/L磷酸盐缓冲液(PBS),培养基为营养琼脂培养基。
检测方法:
依据中华人民共和国卫生行业标准WS/T 650-2019《抗菌和抑菌效果评价方法》5.2.1悬液定量杀菌试验。
杀菌试验:按照悬液定量杀菌试验方法,实施例1原液,作用时间1min、2min、3min,试验重复3次。试验温度20℃±1℃。
检测结果:
铜绿假单胞菌杀菌试验
经3次重复试验证明,在试验温度20℃±1℃的条件下,实施例1原液,作用1min,对铜绿假单胞菌的平均杀菌率为>99.9%(见表6所示)
表6表6实施例1杀菌试验结果
注:阴性对照无菌生长
结果表明,经3次重复试验,实施例1原液,以3.9%D/E中和肉汤为中和剂,可有效中和残留实施例1对铜绿假单胞菌的作用,且中和剂及其中和产物对铜绿假单胞菌及培养基无不良影响。3次重复试验证明,实施例1原液,作用2min,对铜绿假单胞菌的平均杀菌率为>99%,具有较强抗菌作用。
试验例7白色念珠菌杀菌性能检测
试验菌种为白色念珠菌ATCC 10231菌种代数为第5代,中和剂为3.9%D/E中和肉汤,稀释液为0.03mol/L磷酸盐缓冲液(PBS),培养基为营养琼脂培养基。
检测方法:
依据中华人民共和国卫生行业标准WS/T 650-2019《抗菌和抑菌效果评价方法》5.2.1悬液定量杀菌试验。
杀菌试验:按照悬液定量杀菌试验方法,实施例1原液,作用时间1min、
2min、3min,试验重复3次。试验温度20℃±1℃。
检测结果:
白色念珠菌杀菌试验
经3次重复试验证明,在试验温度20℃±1℃的条件下,实施例1原液,作用3min,对白色念珠菌的平均杀菌率为97.6%(见表7所示)
表7表7实施例1杀菌试验结果
注:阴性对照无菌生长
结果表明,经3次重复试验,实施例1原液,以3.9%D/E中和肉汤为中和剂,可有效中和残留实施例1对白色念珠菌的作用,且中和剂及其中和产物对白色念珠菌及培养基无不良影响。3次重复试验证明,实施例1原液,作用3min,对白色念珠菌的平均杀菌率为97.6%,具有较强抗菌作用。
试验例8皮肤消毒现场试验
试验方法:
依据:《消毒技术规范》(2002年版)2.1.2.8消毒剂对皮肤消毒现场试验。
消毒前:让受试者将左右前臂内侧中段互相充分对搓后,将规格板放于受试者左前臂内侧中段表面,用无菌棉拭在含10ml(0.1%吐温80的0.03mol/L磷酸盐缓冲液)稀释液试管中浸湿,于管壁上挤干后,在规格板框定的区域内,横向往返涂擦10遍,纵向往返涂擦3遍,每涂擦一遍,将棉拭转动一次,采样后,以无菌操作方式将棉拭采样端剪入(0.1%吐温80的0.03mol/L磷酸盐缓冲液)稀释液试管内,振打200次,作为阳性对照样本。
取实施例1原液擦拭受试者右前臂内侧规格板框定区域,消毒作用3.0min,用3.9%D/E中和肉汤代替稀释液,与阳性对照组同样的方法对受试者右前臂内侧表面残留的自然菌采样一次,振打200次,作为试验组样本。
分别取未用过的同批中和剂、稀释液作为阴性对照组样本。
受试数量:30人次。试验环境温度21.2℃,相对湿度47%。
试验结果:
经30次重复试验表明,实施例1擦拭作用3.0min,对皮肤表面自然菌的杀灭对数值为>1.00(见表8所示)
表8表8样品对皮肤表面现场消毒试验结果
注:阴性对照无菌生长
结果表明,经30人次试验结果显示,实施例1原液,擦拭作用3.0min,对皮肤表面自然菌的杀灭对数值均>1.00,有较强的抑菌效果。
试验例9急性经口毒性试验
试验方法:
准备实施例1原液,以灭菌水为溶媒,配制成0.25g/ml供试品制备液。SPF级KM小鼠20只,雌雄各半,体重18g~22g作为实验对象。
染毒方法:采用一次最大限度试验,只设5000mg/kg体重一个剂量组。全部动物纳入染毒组。染毒前动物禁食过夜,自由饮水。用灌胃方式将受试样品一次给予动物,染毒体积0.2mL/10g体重。
观察与评价:染毒后观察并记录动物的中毒表现,并对观察期满处死动物进行尸体解剖,肉眼观察,发现有异常的组织或脏器,进一步作组织病理学检查。观察期14d。依据《消毒技术规范》(2002年版)2.3.1.5.2“一次最大限度试验”中的方法计算LD50并根据“评价规定”对毒性进行评价。
检测条件:环境温度:20℃~26℃,相对湿度:40%~70%。
试验结果:
动物染毒后连续观察14d未出现其他异常表现和死亡(见表9),观察期满处死动物进行尸体解剖,经肉眼观察各主要脏器均未见异常。
表9表9KM小鼠急性经口毒性试验结果
结果表明,实施例1按《消毒技术规范》(2002年版)2.3.1急性经口毒性试验进行检测,对KM小鼠的急性经口毒性LDS0>5000mg/kg体重,毒性分级属实际无毒。
通过试验例1、试验例2、试验例3、试验例4、试验例6、试验例7、试验例8和试验例9,表明本发明在具有优秀的保湿效果,兼具优秀的广谱抗菌性能,同时具有优秀的安全性。
Claims (5)
1.一种仿生保湿抗菌修复组合物,其特征在于,包括以下重量百分比组份:
水解壳多糖0.05-5%、季铵盐类化合物0.1-5%、胍类化合物0.1-5%、醇类化合物0.1-20%、吡咯烷酮羧酸钠0.1-20%、马齿苋提取物0.1-10%、EDTA二钠0.05-5%、甜菜碱0.1-10%和纯化水25-99.35%。
2.根据权利要求1所述的一种仿生保湿抗菌修复组合物,其特征在于,所述的季铵盐类化合物为O-3,4-亚甲二氧基乙酸酯-N-三甲基壳聚糖季铵盐、双癸基二甲基氯化铵、辛基癸基二甲基氯化铵、十二烷基二甲基苄基氯化铵中一种或多种的混合物。
3.根据权利要求1所述的一种仿生保湿抗菌修复组合物,其特征在于,所述的胍类化合物为聚六亚甲基双胍、聚氨丙基双胍、聚六亚甲基胍中一种或多种的混合物。
4.根据权利要求1所述的一种仿生保湿抗菌修复组合物,其特征在于,所述的醇类化合物为乙醇、甘油、丙二醇、丁二醇、1,2-己二醇、苯氧乙醇、山梨醇中一种或多种的混合物。
5.根据权利要求1-4任意一项所述的一种仿生保湿抗菌修复组合物,其特征在于,包括一下制备步骤:将水解壳多糖、季铵盐类化合物、胍类化合物、醇类化合物、吡咯烷酮羧酸钠、马齿苋提取物、EDTA二钠、甜菜碱依次加入纯化水中溶解均匀,得到仿生保湿抗菌修复组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410019999.8A CN117815146A (zh) | 2024-01-06 | 2024-01-06 | 一种仿生保湿抗菌修复组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410019999.8A CN117815146A (zh) | 2024-01-06 | 2024-01-06 | 一种仿生保湿抗菌修复组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117815146A true CN117815146A (zh) | 2024-04-05 |
Family
ID=90523966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410019999.8A Pending CN117815146A (zh) | 2024-01-06 | 2024-01-06 | 一种仿生保湿抗菌修复组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117815146A (zh) |
-
2024
- 2024-01-06 CN CN202410019999.8A patent/CN117815146A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9814737B2 (en) | Composition for skin sanitization and protection and method of its use | |
MX2014006654A (es) | Composiciones biocidas y métodos para utilizar las mismas. | |
US20220143077A1 (en) | Antimicrobial and cleansing composition | |
KR101500514B1 (ko) | 피부자극이 없는 방부제 조성물을 함유하는 물티슈 | |
CN1265842C (zh) | 免洗消毒凝胶及制备方法 | |
DK169904B1 (da) | Anvendelse af esterforbindelser som temporært mikrobicid | |
KR20080081633A (ko) | 항균비누 조성물 | |
RU2359704C2 (ru) | Антисептическое и дезинфицирующее средство | |
DK2170081T3 (en) | Antimicrobial preparations | |
CN117815146A (zh) | 一种仿生保湿抗菌修复组合物 | |
CN113440428B (zh) | 一种适用于多类表面活性剂体系的高效温和抑菌剂及其应用 | |
CN111920911B (zh) | 一种防蚊消毒剂及制备方法 | |
CN113521042A (zh) | 一种儿童专用无醇免洗病毒灭活消毒剂及其制备方法 | |
CN113876680A (zh) | 一种植物湿巾及其制备工艺 | |
CN104784164A (zh) | 一种蛋白皮肤清洁消毒剂及其制备方法 | |
US11744249B2 (en) | Disinfectants with iodine and copper complexes for use against coronavirus | |
ES2784275B2 (es) | Antiséptico de acción prolongada para el lavado higiénico por fricción y lavado pre-quirúrgico de manos | |
RU2203035C1 (ru) | Фармацевтическая композиция с дезинфицирующими, спороцидными и ранозаживляющими свойствами | |
US20230389553A1 (en) | Disinfectants with iodine and copper complexes for biofilm eradication and prevention | |
RU2517031C1 (ru) | Биоцидный состав для пропитки салфеток | |
CN114631538A (zh) | 大熊猫圈舍用消毒剂、制备方法及消毒方法 | |
Negash et al. | Common Antiseptics: Mechanism Of Action And Its Uses In Animal | |
CN110742905A (zh) | 含银的伤口护理液及制备方法 | |
CZ37412U1 (cs) | Dezinfekční přípravek | |
CN111000764A (zh) | 一种抗菌皮肤清洁用品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |